The structural and functional basis of MET exon 14 activation and acquired drug resistance

MET 外显子 14 激活和获得性耐药的结构和功能基础

• 批准号: 9892984
• 负责人: Eric Collisson
• 金额: $ 40.99万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9892984
• 关键词: Adenocarcinoma; Affinity; Alleles; American; Animals; Automobile Driving; Binding; Biological; Biology; Cancer Etiology; Cancer Patient; Cells; Clinical; Colon Carcinoma; Development; Disease; Drug Modelings; Drug Targeting; Epidermal Growth Factor Receptor; Epithelial; Epithelium; Event; Exons; Fostering; Frequencies; Gene Mutation; Generations; Genes; Genetic; Genomics; Genotype; Goals; Grant; Immunotherapy; In Vitro; Knowledge; Lead; Lung; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Mediating; Medical Oncologist; Mesenchymal; Methods; Missense Mutation; Modeling; Molecular Conformation; Mutate; Mutation; Non-Small-Cell Lung Carcinoma; Oncogenes; Oncoproteins; Outcome; Patients; Pharmaceutical Preparations; Phosphotransferases; Plant Roots; Play; Population; Predisposition; Protein Analysis; Protein Kinase; Publishing; Receptor Protein-Tyrosine Kinases; Receptor Signaling; Recombinants; Recurrence; Research; Resistance; Role; Route; Signal Transduction; Structure; Testing; The Cancer Genome Atlas; Time; acquired drug resistance; cancer type; clinical care; crizotinib; drug sensitivity; druggable target; experience; gene discovery; improved; in vivo; in vivo Model; inhibitor/antagonist; innovation; kinase inhibitor; malignant breast neoplasm; mouse model; precision medicine; pressure; prevent; programmed cell death ligand 1; receptor; resistance mechanism; resistance mutation; response; targeted treatment; therapeutic development; therapy development; tumor

Project Summary/Abstract Summary: Lung cancer is the largest cancer killer but is also a heterogeneous disease in which different oncoproteins contribute to genetic subtypes, some of which carry specific treatments. Despite favorable outcomes when therapies are matched to driving oncogenes, only small fraction of lung cancer patients are treated in a targeted manner. Our goal is to optimize targeted therapy for the large proportion of lung cancer patients harboring activating mutations in the Mesenchymal Epithelial Transformation (MET) gene. Background: MET mutations are the most recent addition to the list of druggable, recurrently mutated kinases in nonsmall cell lung cancer (NSCLC). We have recently defined the frequency of MET aberrations in NSCLC, and identified exon 14 deletion in the juxtamembrane domain of MET as the most common somatic MET event. The mechanism for its action and its susceptibility to existing targeted MET therapies is however poorly defined, preventing targeted treatment of this large population of NSCLC patients. Methods: We will focus on the signaling and structural effects MET exon 14 mutations impart with the goal of understanding the mechanism of action underlying selection for this mutation in NSCLC. We will first characterize the mechanism by which the juxtamembrane segment of MET regulates the kinase, using purified recombinant MET fragments from its intracellular domain. Next, we will study how exon 14 deletions influence MET inhibitors' binding and whether mutation confers affinity for specific classes of kinase inhibitors. Finally, we will model resistance mutations to first generation (Type I) MET inhibitors in vivo, and suggest strategies to overcome them using targeted approaches with Type II inhibitors and “off-MET” drug targets. Impact: This project focuses on a common and understudied mutation in lung cancer, the most lethal cancer type, by far. Thousands of Americans die each year with MET-mutated lung cancer, and often do so without being considered for targeted therapy against their tumor's genotype. We will clarify the role MET mutation plays in lung cancer and will structurally define how the most common mutations activate this oncoprotein. This project will foster development of therapies targeting MET exon 14 mutations, and optimize approaches to targeting the most common anticipated routes of resistance.

项目摘要/摘要 摘要：肺癌是最大的癌症杀手，但也是一种不同类型的疾病 癌蛋白对遗传亚型有贡献，其中一些亚型具有特定的治疗方法。尽管是有利的 结果当治疗与致癌基因匹配时，只有一小部分肺癌患者的治疗结果与癌基因匹配 以有针对性的方式处理。我们的目标是优化很大比例肺癌的靶向治疗 存在间充质上皮转化(MET)基因激活突变的患者。 背景：MET突变是最新增加的可用药、反复突变的激酶 非小细胞肺癌(NSCLC)。我们最近定义了非小细胞肺癌中MET像差的频率， MET膜旁区域14号外显子缺失是最常见的体细胞MET事件。 然而，其作用机制及其对现有靶向MET疗法的敏感性尚不明确， 阻止对这一大群非小细胞肺癌患者进行有针对性的治疗。 方法：我们将重点研究MET外显子14突变所传递的信号和结构效应，目的是 了解在非小细胞肺癌中选择该突变的作用机制。我们将首先 用纯化的MET的膜旁片段来描述其调节激酶的机制 重组的MET片段来自其胞内区。接下来，我们将研究外显子14的缺失如何影响 MET抑制剂的结合，以及突变是否使特定类别的激酶抑制剂具有亲和力。最后， 我们将在体内模拟对第一代(I型)MET抑制剂的耐药性突变，并提出策略以 使用有针对性的方法，使用II型抑制剂和“未达到目标”的药物靶点来克服这些障碍。 影响：这个项目关注的是肺癌中一种常见且未被充分研究的突变，肺癌是最致命的癌症 打字，到目前为止。每年有数以千计的美国人死于MET突变的肺癌，而且往往是在没有MET突变的情况下 正在考虑针对他们的肿瘤基因进行靶向治疗。我们将澄清MET突变的角色 在肺癌中发挥作用，并将在结构上定义最常见的突变如何激活这种癌蛋白。 该项目将促进针对MET外显子14突变的治疗方法的开发，并优化方法以 目标是最常见的预期抵抗路线。